These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
339 related articles for article (PubMed ID: 26768236)
1. B-Raf Inhibition in the Clinic: Present and Future. Fiskus W; Mitsiades N Annu Rev Med; 2016; 67():29-43. PubMed ID: 26768236 [TBL] [Abstract][Full Text] [Related]
2. [Progress of anti-tumor study based on BRAF]. Yan GR; Xu ZJ; Wang HY; Zhu WL Yao Xue Xue Bao; 2012 Dec; 47(12):1567-74. PubMed ID: 23460959 [TBL] [Abstract][Full Text] [Related]
3. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819 [TBL] [Abstract][Full Text] [Related]
4. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323 [TBL] [Abstract][Full Text] [Related]
5. Mechanisms of resistance to RAF inhibition in melanomas harboring a BRAF mutation. Chapman PB Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714462 [TBL] [Abstract][Full Text] [Related]
6. Targeted therapies for cutaneous melanoma. Kee D; McArthur G Hematol Oncol Clin North Am; 2014 Jun; 28(3):491-505. PubMed ID: 24880943 [TBL] [Abstract][Full Text] [Related]
7. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Johannessen CM; Boehm JS; Kim SY; Thomas SR; Wardwell L; Johnson LA; Emery CM; Stransky N; Cogdill AP; Barretina J; Caponigro G; Hieronymus H; Murray RR; Salehi-Ashtiani K; Hill DE; Vidal M; Zhao JJ; Yang X; Alkan O; Kim S; Harris JL; Wilson CJ; Myer VE; Finan PM; Root DE; Roberts TM; Golub T; Flaherty KT; Dummer R; Weber BL; Sellers WR; Schlegel R; Wargo JA; Hahn WC; Garraway LA Nature; 2010 Dec; 468(7326):968-72. PubMed ID: 21107320 [TBL] [Abstract][Full Text] [Related]
9. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Van Allen EM; Wagle N; Sucker A; Treacy DJ; Johannessen CM; Goetz EM; Place CS; Taylor-Weiner A; Whittaker S; Kryukov GV; Hodis E; Rosenberg M; McKenna A; Cibulskis K; Farlow D; Zimmer L; Hillen U; Gutzmer R; Goldinger SM; Ugurel S; Gogas HJ; Egberts F; Berking C; Trefzer U; Loquai C; Weide B; Hassel JC; Gabriel SB; Carter SL; Getz G; Garraway LA; Schadendorf D; Cancer Discov; 2014 Jan; 4(1):94-109. PubMed ID: 24265153 [TBL] [Abstract][Full Text] [Related]
10. New RAF kinase inhibitors in cancer therapy. Martin-Liberal J; Larkin J Expert Opin Pharmacother; 2014 Jun; 15(9):1235-45. PubMed ID: 24766074 [TBL] [Abstract][Full Text] [Related]
11. BRAF inhibitor therapy in HCL. Dietrich S; Zenz T Best Pract Res Clin Haematol; 2015 Dec; 28(4):246-52. PubMed ID: 26614903 [TBL] [Abstract][Full Text] [Related]
12. Improved overall survival in melanoma with combined dabrafenib and trametinib. Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551 [TBL] [Abstract][Full Text] [Related]
13. Dabrafenib therapy for advanced melanoma. Trinh VA; Davis JE; Anderson JE; Kim KB Ann Pharmacother; 2014 Apr; 48(4):519-29. PubMed ID: 24259661 [TBL] [Abstract][Full Text] [Related]